3 results
Approved WMOCompleted
In this study, plerixafor, the study drug, will be given in addition to GCSF to see if it works the same way in children as in adults.
Approved WMOCompleted
The primary objective of this study is to evaluate the efficacy of TDF plus Peginterferon *-2a (PEG) combination therapy for 48 weeks versus standard of care TDF monotherapy or PEG monotherapy for 48 weeks in non-cirrhotic CHB subjects as determined…
Approved WMOWill not start
To demonstrate that Plerixafor is able to reduce the need for invasive mechanical ventilation or death in severe COVID-19 patients admitted in Intensive Care Unit (ICU)